Trinity Biotech plc TRBA.F Stock
Trinity Biotech plc Price Chart
Trinity Biotech plc TRBA.F Financial and Trading Overview
Trinity Biotech plc stock price | 0.42 EUR |
Previous Close | 0.93 EUR |
Open | 0.91 EUR |
Bid | 0.91 EUR x 30200 |
Ask | 1 EUR x 29000 |
Day's Range | 0.91 - 0.91 EUR |
52 Week Range | 0.73 - 1.39 EUR |
Volume | 625 EUR |
Avg. Volume | 13 EUR |
Market Cap | 38.23M EUR |
Beta (5Y Monthly) | 1.41338 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | June 5, 2015 |
1y Target Est | N/A |
TRBA.F Valuation Measures
Enterprise Value | 99.44M EUR |
Trailing P/E | N/A |
Forward P/E | -22.750002 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.5112631 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 1.33 |
Enterprise Value/EBITDA | -10.444 |
Trading Information
Trinity Biotech plc Stock Price History
Beta (5Y Monthly) | 1.41338 |
52-Week Change | -20.27% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1.39 EUR |
52 Week Low | 0.73 EUR |
50-Day Moving Average | 0.83 EUR |
200-Day Moving Average | 1.01 EUR |
TRBA.F Share Statistics
Avg. Volume (3 month) | 13 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 38.21M |
Float | 21.74M |
Short Ratio | N/A |
% Held by Insiders | 35.65% |
% Held by Institutions | 17.22% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -54.84% |
Operating Margin (ttm) | -14.60% |
Gross Margin | 29.48% |
EBITDA Margin | -12.73% |
Management Effectiveness
Return on Assets (ttm) | -6.46% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 74.78M EUR |
Revenue Per Share (ttm) | 2.22 EUR |
Quarterly Revenue Growth (yoy) | -7.59% |
Gross Profit (ttm) | N/A |
EBITDA | -9521000 EUR |
Net Income Avi to Common (ttm) | -41002000 EUR |
Diluted EPS (ttm) | -1.05 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 6.58M EUR |
Total Cash Per Share (mrq) | 0.17 EUR |
Total Debt (mrq) | 72.2M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 2.692 |
Book Value Per Share (mrq) | -0.057 |
Cash Flow Statement
Operating Cash Flow (ttm) | -921000 EUR |
Levered Free Cash Flow (ttm) | -8472750 EUR |
Profile of Trinity Biotech plc
Country | Germany |
State | N/A |
City | Bray |
Address | IDA Business Park |
ZIP | A98 H5C8 |
Phone | 353 1 276 9800 |
Website | https://www.trinitybiotech.com |
Industry | Diagnostics & Research |
Sector(s) | Healthcare |
Full Time Employees | 398 |
Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Q&A For Trinity Biotech plc Stock
What is a current TRBA.F stock price?
Trinity Biotech plc TRBA.F stock price today per share is 0.42 EUR.
How to purchase Trinity Biotech plc stock?
You can buy TRBA.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Trinity Biotech plc?
The stock symbol or ticker of Trinity Biotech plc is TRBA.F.
Which industry does the Trinity Biotech plc company belong to?
The Trinity Biotech plc industry is Diagnostics & Research.
How many shares does Trinity Biotech plc have in circulation?
The max supply of Trinity Biotech plc shares is 38.21M.
What is Trinity Biotech plc Price to Earnings Ratio (PE Ratio)?
Trinity Biotech plc PE Ratio is 0.00000000 now.
What was Trinity Biotech plc earnings per share over the trailing 12 months (TTM)?
Trinity Biotech plc EPS is 0 EUR over the trailing 12 months.
Which sector does the Trinity Biotech plc company belong to?
The Trinity Biotech plc sector is Healthcare.